NFPA
MCID: NNF007
MIFTS: 39

Non-Functioning Pituitary Adenoma (NFPA)

Categories: Cancer diseases, Endocrine diseases, Rare diseases

Aliases & Classifications for Non-Functioning Pituitary Adenoma

MalaCards integrated aliases for Non-Functioning Pituitary Adenoma:

Name: Non-Functioning Pituitary Adenoma 58 17
Non-Functioning Pituitary Gland Neoplasm 70
Nfpa 58

Characteristics:

Orphanet epidemiological data:

58
non-functioning pituitary adenoma
Inheritance: Not applicable; Prevalence: 1-9/100000 (Worldwide),1-9/100000 (Finland),1-9/100000 (Sweden),6-9/10000 (Belgium),6-9/10000 (Switzerland),6-9/10000 (United Kingdom),6-9/10000 (Finland);

Classifications:

Orphanet: 58  
Rare endocrine diseases


Summaries for Non-Functioning Pituitary Adenoma

MalaCards based summary : Non-Functioning Pituitary Adenoma, also known as non-functioning pituitary gland neoplasm, is related to pituitary adenoma and adenoma. An important gene associated with Non-Functioning Pituitary Adenoma is SST (Somatostatin), and among its related pathways/superpathways is Growth hormone receptor signaling. The drugs Pasireotide and Somatostatin have been mentioned in the context of this disorder. Affiliated tissues include pituitary, ovary and hypothalamus, and related phenotypes are hypotension and vomiting

Related Diseases for Non-Functioning Pituitary Adenoma

Diseases related to Non-Functioning Pituitary Adenoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 107)
# Related Disease Score Top Affiliating Genes
1 pituitary adenoma 31.6 SST GHR GH1
2 adenoma 31.5 SST MUC1 GH1
3 pituitary tumors 31.1 SST GH1
4 pituitary apoplexy 30.9 SST GH1
5 functioning pituitary adenoma 30.6 SST S100B GHR GH1 FAM90A1 CDK6
6 acromegaly 30.5 SST GHR GH1
7 pituitary gland disease 30.1 SST GHR GH1
8 meningioma, familial 29.7 SST S100B MUC1
9 hypopituitarism 10.6
10 hypogonadism 10.4
11 diabetes insipidus 10.3
12 tsh producing pituitary tumor 10.2 SST GH1
13 pituitary-dependent cushing's disease 10.2 SST GH1
14 kearns-sayre syndrome 10.2
15 hyperprolactinemia 10.2
16 secondary adrenal insufficiency 10.2
17 headache 10.2
18 pituitary adenoma 1, multiple types 10.2 SST GH1
19 vipoma 10.2 SST GH1
20 pancreatoblastoma 10.1 SST MUC1
21 fibrous dysplasia 10.1 SST GH1
22 duodenum cancer 10.1 SST MUC1
23 duodenum disease 10.1 SST MUC1
24 villous adenoma 10.1 SST MUC1
25 dwarfism 10.1 GHR GH1
26 pituitary hormone deficiency, combined, 2 10.1 GHR GH1
27 subependymal giant cell astrocytoma 10.1 SST S100B
28 laron syndrome 10.1 GHR GH1
29 sclerosing perineurioma 10.1 S100B MUC1
30 perineurioma 10.1 S100B MUC1
31 localized hypertrophic neuropathy 10.1 S100B MUC1
32 reticular perineurioma 10.1 S100B MUC1
33 type 2 diabetes mellitus 10.1
34 chordoma 10.1
35 galactorrhea 10.1
36 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.1
37 ocular motor apraxia 10.1
38 3-methylglutaconic aciduria, type iii 10.1
39 hypothyroidism, congenital, nongoitrous, 4 10.1
40 oncocytoma 10.1
41 retinitis pigmentosa 11 10.1
42 yemenite deaf-blind hypopigmentation syndrome 10.1
43 premature ovarian failure 7 10.1
44 ptosis 10.1
45 intracranial meningioma 10.1
46 conn's syndrome 10.1
47 amenorrhea 10.1
48 hypothyroidism 10.1
49 gangliocytoma 10.1
50 inappropriate adh syndrome 10.1

Graphical network of the top 20 diseases related to Non-Functioning Pituitary Adenoma:



Diseases related to Non-Functioning Pituitary Adenoma

Symptoms & Phenotypes for Non-Functioning Pituitary Adenoma

Human phenotypes related to Non-Functioning Pituitary Adenoma:

58 31 (show top 50) (show all 61)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 hypotension 58 31 frequent (33%) Frequent (79-30%) HP:0002615
2 vomiting 58 31 frequent (33%) Frequent (79-30%) HP:0002013
3 fatigue 58 31 frequent (33%) Frequent (79-30%) HP:0012378
4 progressive visual loss 58 31 frequent (33%) Frequent (79-30%) HP:0000529
5 increased circulating gonadotropin level 58 31 frequent (33%) Frequent (79-30%) HP:0000837
6 pallor 58 31 frequent (33%) Frequent (79-30%) HP:0000980
7 easy fatigability 58 31 frequent (33%) Frequent (79-30%) HP:0003388
8 headache 58 31 frequent (33%) Frequent (79-30%) HP:0002315
9 impotence 58 31 frequent (33%) Frequent (79-30%) HP:0000802
10 decreased fertility in males 58 31 frequent (33%) Frequent (79-30%) HP:0012041
11 male hypogonadism 58 31 frequent (33%) Frequent (79-30%) HP:0000026
12 irregular menstruation 58 31 frequent (33%) Frequent (79-30%) HP:0000858
13 pituitary hypothyroidism 58 31 frequent (33%) Frequent (79-30%) HP:0008245
14 adrenocorticotropic hormone deficiency 58 31 frequent (33%) Frequent (79-30%) HP:0011748
15 decreased fertility in females 58 31 frequent (33%) Frequent (79-30%) HP:0000868
16 female hypogonadism 58 31 frequent (33%) Frequent (79-30%) HP:0000134
17 decreased circulating acth level 58 31 frequent (33%) Frequent (79-30%) HP:0002920
18 secondary growth hormone deficiency 58 31 frequent (33%) Frequent (79-30%) HP:0008240
19 increased intraabdominal fat 58 31 frequent (33%) Frequent (79-30%) HP:0008993
20 anemia of inadequate production 58 31 frequent (33%) Frequent (79-30%) HP:0010972
21 adrenocorticotropin deficient adrenal insufficiency 58 31 frequent (33%) Frequent (79-30%) HP:0011735
22 decreased female libido 58 31 frequent (33%) Frequent (79-30%) HP:0030018
23 abnormal hair quantity 31 frequent (33%) HP:0011362
24 hypogonadotropic hypogonadism 31 frequent (33%) HP:0000044
25 ptosis 58 31 occasional (7.5%) Occasional (29-5%) HP:0000508
26 diplopia 58 31 occasional (7.5%) Occasional (29-5%) HP:0000651
27 blindness 58 31 occasional (7.5%) Occasional (29-5%) HP:0000618
28 vertigo 58 31 occasional (7.5%) Occasional (29-5%) HP:0002321
29 panhypopituitarism 58 31 occasional (7.5%) Occasional (29-5%) HP:0000871
30 oculomotor nerve palsy 58 31 occasional (7.5%) Occasional (29-5%) HP:0012246
31 central diabetes insipidus 58 31 occasional (7.5%) Occasional (29-5%) HP:0000863
32 sudden loss of visual acuity 58 31 occasional (7.5%) Occasional (29-5%) HP:0001117
33 macroorchidism, postpubertal 58 31 occasional (7.5%) Occasional (29-5%) HP:0002050
34 cranial nerve vi palsy 58 31 occasional (7.5%) Occasional (29-5%) HP:0006897
35 fourth cranial nerve palsy 58 31 occasional (7.5%) Occasional (29-5%) HP:0007011
36 internal ophthalmoplegia 58 31 occasional (7.5%) Occasional (29-5%) HP:0007942
37 increased serum testosterone level 58 31 occasional (7.5%) Occasional (29-5%) HP:0030088
38 bitemporal hemianopia 58 31 occasional (7.5%) Occasional (29-5%) HP:0030521
39 seizure 31 occasional (7.5%) HP:0001250
40 reduced circulating prolactin concentration 31 occasional (7.5%) HP:0008202
41 seizures 58 Occasional (29-5%)
42 nausea and vomiting 58 Frequent (79-30%)
43 macroorchidism 58 Occasional (29-5%)
44 cranial nerve paralysis 58 Occasional (29-5%)
45 hypogonadotrophic hypogonadism 58 Frequent (79-30%)
46 anterior hypopituitarism 58 Frequent (79-30%)
47 diabetes insipidus 58 Occasional (29-5%)
48 abnormality of the menstrual cycle 58 Frequent (79-30%)
49 erectile dysfunction 58 Frequent (79-30%)
50 hypogonadism 58 Frequent (79-30%)

Drugs & Therapeutics for Non-Functioning Pituitary Adenoma

Drugs for Non-Functioning Pituitary Adenoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 11)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pasireotide Approved Phase 2, Phase 3 396091-73-9 9941444
2
Somatostatin Approved, Investigational Phase 2, Phase 3 51110-01-1, 38916-34-6 53481605
3
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
4
Cabergoline Approved Phase 3 81409-90-7 54746
5 Hormones Phase 2, Phase 3
6 Hormone Antagonists Phase 2, Phase 3
7 Neurotransmitter Agents Phase 3
8 Dopamine Agents Phase 3
9 Dopamine agonists Phase 3
10 Antiparkinson Agents Phase 3
11 Pharmaceutical Solutions Phase 2

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Somatostatin and Dopamine Receptors Expression in Non-functioning Pituitary Adenomas and Resistant Prolactinomas: Correlation With in Vitro and in Vivo Responsiveness to Somatostatin Analogs and Dopamine Agonist Completed NCT01620138 Phase 2, Phase 3 Pasireotide;cabergoline
2 Dopamine Agonist Treatment of Non-functioning Pituitary Adenomas (NFPAs) - a Randomized Controlled Trial Recruiting NCT02288962 Phase 3 cabergoline
3 An Open-Label, Single Arm, Phase II Study to Evaluate the Efficacy and Safety of Pasireotide LAR on the Treatment of Patients With Clinically Non-Functioning Pituitary Adenoma Completed NCT01283542 Phase 2 Pasireotide LAR
4 A One Year, Randomized, Double-Blind, Placebo-Controlled Study of TBR-760 in Adult Patients With Non-Functioning Pituitary Adenomas Not yet recruiting NCT04335357 Phase 2 TBR-760;Placebo
5 Exploratory Phase 2 Study of Farletuzumab in Resectable Non-functioning Pituitary Adenoma Withdrawn NCT01203618 Phase 2 Farletuzumab
6 Predictive Factors of Recurrence of Non Functioning Pituitary Adenomas : a Retrospective Study of 220 Patients in the Reims University Hospital, France Completed NCT02803697

Search NIH Clinical Center for Non-Functioning Pituitary Adenoma

Genetic Tests for Non-Functioning Pituitary Adenoma

Anatomical Context for Non-Functioning Pituitary Adenoma

MalaCards organs/tissues related to Non-Functioning Pituitary Adenoma:

40
Pituitary, Ovary, Hypothalamus, Prostate

Publications for Non-Functioning Pituitary Adenoma

Articles related to Non-Functioning Pituitary Adenoma:

(show top 50) (show all 208)
# Title Authors PMID Year
1
Chiasmapexy for secondary empty sella syndrome: diagnostic and therapeutic considerations. 61
33136230 2021
2
Identifying critical protein-coding genes and long non-coding RNAs in non-functioning pituitary adenoma recurrence. 61
33664827 2021
3
Giant Non-Functioning Pituitary Adenoma: Clinical Characteristics and Therapeutic Outcomes. 61
31896156 2021
4
Nomogram predictive model of post-operative recurrence in non-functioning pituitary adenoma. 61
33708562 2021
5
Incidence, mortality, and cardiovascular diseases in pituitary adenoma in Korea: a nationwide population-based study. 61
32949324 2021
6
Health-related quality of life in patients with non-functioning pituitary adenoma: a special focus on hydrocortisone replacement dose. 61
32737686 2020
7
Chromosomal and oxidative DNA damage in non-functioning pituitary adenomas. 61
33295635 2020
8
ESE audit on management of Adult Growth Hormone Deficiency in clinical practice. 61
33320830 2020
9
Cephalocaudal tumor diameter is a predictor of diabetes insipidus after endoscopic transsphenoidal surgery for non-functioning pituitary adenoma. 61
33191457 2020
10
Characteristics and clinical outcomes in pituitary incidentalomas and non-incidental pituitary tumors treated with endoscopic transsphenoidal surgery. 61
33126308 2020
11
Identification of a multidimensional transcriptome signature predicting tumor regrowth of clinically non‑functioning pituitary adenoma. 61
32582995 2020
12
Cell proliferation, apoptosis, and angiogenesis in non-functional pituitary adenoma: association with tumor invasiveness. 61
32656696 2020
13
MRI radiomics for the prediction of recurrence in patients with clinically non-functioning pituitary macroadenomas. 61
32860977 2020
14
The GALANT trial: study protocol of a randomised placebo-controlled trial in patients with a 68Ga -DOTATATE PET-positive, clinically non-functioning pituitary macroadenoma on the effect of lan reotide on t umour size. 61
32792446 2020
15
Full Remission of Long-Term Premenstrual Dysphoric Disorder-Like Symptoms Following Resection of a Pituitary Adenoma: Case Report. 61
32769963 2020
16
Quality of care evaluation in non-functioning pituitary adenoma with chiasm compression: visual outcomes and timing of intervention clinical recommendations based on a systematic literature review and cohort study. 61
32419072 2020
17
Comparative analysis of rhinologic outcomes in Cushing disease and non-functioning pituitary adenoma in patients submitted to endoscopic endonasal transsphenoidal surgery. 61
32346754 2020
18
Correction to: Quality of care evaluation in non-functioning pituitary adenoma with chiasm compression: visual outcomes and timing of intervention clinical recommendations based on a systematic literature review and cohort study. 61
32567033 2020
19
The quality of life after transnasal microsurgical and endoscopic resection of nonfunctioning pituitary adenoma. 61
32745380 2020
20
Current Status of Diagnosis and Management for Functioning Pituitary Tumors: Part I. 61
32611887 2020
21
Non-functioning pituitary adenomas and pregnancy: one-center experience and review of the literature. 61
32267360 2020
22
Cut-off values for sufficient cortisol response to low dose Short Synacthen Test after surgery for non-functioning pituitary adenoma. 61
31907611 2020
23
Integrated analysis of DNA methylation and mRNA expression profiles to identify key genes involved in the regrowth of clinically non-functioning pituitary adenoma. 61
32015217 2020
24
Preoperative growth hormone (GH) peak values during a GH releasing peptide-2 test reflect the severity of hypopituitarism and the postoperative recovery of GH secretion in patients with non-functioning pituitary adenomas. 61
31776295 2020
25
Pseudoacromegaly Associated with Non-Functioning Pituitary Adenoma. 61
33313006 2020
26
Dome-Shaped Pituitary Enlargement in Primary Hypothyroidism: Avoiding Neurosurgical Interventions. 61
33442197 2020
27
Giant Non-Functioning Pituitary Adenoma: Clinical Characteristics and Therapeutic Outcomes. 61
31931533 2020
28
Identification of key genes in invasive clinically non-functioning pituitary adenoma by integrating analysis of DNA methylation and mRNA expression profiles. 61
31796052 2019
29
NON-FUNCTIONAL PITUITARY TUMORS: A MISLEADING PRESENTATION OF AN INTRASELLAR PLASMACYTOMA. 61
32377251 2019
30
Cavernous sinus haemangioma with intrasellar extension mimicking non-functioning pituitary adenoma - A case report and review of literature. 61
31406488 2019
31
Identification of CDK6 and RHOU in Serum Exosome as Biomarkers for the Invasiveness of Non-functioning Pituitary Adenoma. 61
31601299 2019
32
Significance of Elevated HMGB1 Expression in Pituitary Apoplexy. 61
31366550 2019
33
Autoimmune thyroid diseases are more common in patients with prolactinomas: a retrospective case-control study in an Italian cohort. 61
30406929 2019
34
Unexpected concomitant pituitary adenoma and suprasellar meningioma: a case report and review of the literature. 61
31204511 2019
35
Endocrinological Outcome of Endoscopic Transsphenoidal Surgery for Functioning and Non-Functioning Pituitary Adenoma. 61
31303851 2019
36
Predicting the regrowth of clinically non-functioning pituitary adenoma with a statistical model. 61
31109334 2019
37
The burden of disease for pituitary patients. 61
31405752 2019
38
Quality of Life but not Cognition is Impacted by Radiotherapy in Patients with Non-Functioning Pituitary Adenoma. 61
30861564 2019
39
Intractable Rathke's cleft cyst hidden behind co-existing giant pituitary adenoma - Case report. 61
30610983 2019
40
Incidence rate and risk factors of early repolarization in patients with growth hormone-secreting pituitary adenoma: a cohort study. 61
30643415 2019
41
Genome-wide identification of lncRNAs and mRNAs differentially expressed in non-functioning pituitary adenoma and construction of an lncRNA-mRNA co-expression network. 61
30504132 2019
42
Endocrinological Outcomes of Intraoperative MRI-Guided Endoscopic Transsphenoidal Surgery for Non-Functioning Pituitary Adenoma. 61
30649793 2019
43
A two‑circRNA signature predicts tumour recurrence in clinical non‑functioning pituitary adenoma. 61
30542712 2019
44
Recurrence in silent corticotroph adenomas after primary treatment: A systematic review and meta-analysis. 61
30590584 2018
45
FGFR2 gene polymorphism rs2981582 is associated with non-functioning pituitary adenomas in Chinese Han population: a case-control study. 61
30206133 2018
46
Spindle cell oncocytoma of the neurohypophysis with metastasis to the sphenoparietal sinus and immunohistochemical negativity for S100 and epithelial membrane antigen (EMA). 61
30431381 2018
47
Comorbidities in patients with non-functioning pituitary adenoma: influence of long-term growth hormone replacement 61
30299891 2018
48
Non-invasive radiomics approach potentially predicts non-functioning pituitary adenomas subtypes before surgery. 61
29572634 2018
49
Postoperative growth hormone dynamics in clinically nonfunctioning pituitary adenoma. 61
29910227 2018
50
Data of phosphoproteomic analysis of non-functioning pituitary adenoma. 61
29900237 2018

Variations for Non-Functioning Pituitary Adenoma

Expression for Non-Functioning Pituitary Adenoma

Search GEO for disease gene expression data for Non-Functioning Pituitary Adenoma.

Pathways for Non-Functioning Pituitary Adenoma

Pathways related to Non-Functioning Pituitary Adenoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
10.24 GHR GH1

GO Terms for Non-Functioning Pituitary Adenoma

Cellular components related to Non-Functioning Pituitary Adenoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth hormone receptor complex GO:0070195 8.62 GHR GH1

Biological processes related to Non-Functioning Pituitary Adenoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine-mediated signaling pathway GO:0019221 9.54 RHOU MUC1 GHR
2 positive regulation of JAK-STAT cascade GO:0046427 9.32 GHR GH1
3 positive regulation of multicellular organism growth GO:0040018 9.26 GHR GH1
4 negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator GO:1902166 9.16 MUC1 ING2
5 JAK-STAT cascade involved in growth hormone signaling pathway GO:0060397 8.96 GHR GH1
6 growth hormone receptor signaling pathway GO:0060396 8.62 GHR GH1

Sources for Non-Functioning Pituitary Adenoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....